Law360, New York (August 17, 2010, 7:39 PM ET) -- Pennsylvania's high court has ruled that Johnson & Johnson unit Janssen Pharmaceutica Inc. lacks standing to challenge the state's decision to hire outside counsel to represent it in a now-closed suit accusing the drugmaker of improperly marketing the antipsychotic drug Risperdal.
In a 5-1 decision, the Supreme Court of Pennsylvania on Tuesday affirmed the trial court's order denying Janssen's motion to disqualify contingent fee counsel Bailey Perrin Bailey — which was retained by the Commonwealth's Office of General Counsel — ruling that “the plain and unambiguous...
Pa. Court Refuses To Nix Counsel In Risperdal Suit
To view the full article, take a free trial now.
